-+ 0.00%
-+ 0.00%
-+ 0.00%

Kyntra Bio says Phase 3 MATTERHORN post-hoc analysis shows roxadustat lifts transfusion independence in lower-risk MDS

PUBT·06/11/2026 20:05:47
Listen to the news
Kyntra Bio says Phase 3 MATTERHORN post-hoc analysis shows roxadustat lifts transfusion independence in lower-risk MDS
  • Kyntra Bio flagged new post hoc Phase 3 MATTERHORN data on roxadustat in lower-risk MDS anemia, set for presentation at EHA 2026.
  • The analysis showed higher transfusion independence with roxadustat versus placebo, supporting a potential differentiated option in a hard-to-treat setting.
  • Benefits appeared consistent across ring sideroblast-positive and ring sideroblast-negative disease, widening the potential addressable patient pool.
  • A pivotal Phase 3 trial in high transfusion burden patients is being finalized with FDA input, with initiation targeted for 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606111605PRIMZONEFULLFEED9745798) on June 11, 2026, and is solely responsible for the information contained therein.